Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reiki Nishimura

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Breast Cancer (Tokyo, Japan)|August 25, 2006
Adjuvant therapy for breast cancer in KyushuShinichi Wakamatsu, Shoshu Mitsuyama, Kiyoshi Nanba, et al.
Breast (Edinburgh, Scotland)|January 6, 2017
Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanesShigeto Maeda, Michiyo Saimura, Shigeki Minami, et al.
Anti-Cancer Drugs|September 4, 2008
Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trialReiki Nishimura, Takeshi Tominaga, Morihiko Kimura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 31, 2002
[Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents]Toru Watanabe, Muneaki Sano, Masakazu Toi, et al.
The Lancet. Oncology|January 24, 2012
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trialNorikazu Masuda, Yasuaki Sagara, Takayuki Kinoshita, et al.
Oncology Reports|March 1, 2013
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trialReiki Nishimura, Keisei Anan, Yutaka Yamamoto, et al.
Surgical Oncology|December 14, 2020
The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trialTakeshi Yamaguchi, Yasuo Hozumi, Yasuaki Sagara, et al.
Cancer Science|January 19, 2018
Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II studyNorikazu Masuda, Reiki Nishimura, Masato Takahashi, et al.
British Journal of Cancer|September 4, 2021
Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancerHirofumi Mukai, Yukari Uemura, Hiromitsu Akabane, et al.
The International Journal of Biological Markers|January 16, 2015
Androgen receptor and enzymes in lymph node metastasis and cancer reoccurrence in triple-negative breast cancerKeely May McNamara, Tomomi Yoda, Yasuhiro Miki, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Breast Cancer (Tokyo, Japan)|August 25, 2006
Adjuvant therapy for breast cancer in KyushuShinichi Wakamatsu, Shoshu Mitsuyama, Kiyoshi Nanba, et al.
Breast (Edinburgh, Scotland)|January 6, 2017
Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanesShigeto Maeda, Michiyo Saimura, Shigeki Minami, et al.
Anti-Cancer Drugs|September 4, 2008
Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trialReiki Nishimura, Takeshi Tominaga, Morihiko Kimura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 31, 2002
[Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents]Toru Watanabe, Muneaki Sano, Masakazu Toi, et al.
The Lancet. Oncology|January 24, 2012
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trialNorikazu Masuda, Yasuaki Sagara, Takayuki Kinoshita, et al.
Oncology Reports|March 1, 2013
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trialReiki Nishimura, Keisei Anan, Yutaka Yamamoto, et al.
Surgical Oncology|December 14, 2020
The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trialTakeshi Yamaguchi, Yasuo Hozumi, Yasuaki Sagara, et al.
Cancer Science|January 19, 2018
Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II studyNorikazu Masuda, Reiki Nishimura, Masato Takahashi, et al.
British Journal of Cancer|September 4, 2021
Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancerHirofumi Mukai, Yukari Uemura, Hiromitsu Akabane, et al.
The International Journal of Biological Markers|January 16, 2015
Androgen receptor and enzymes in lymph node metastasis and cancer reoccurrence in triple-negative breast cancerKeely May McNamara, Tomomi Yoda, Yasuhiro Miki, et al.
Pageof 8